Clinically Bharat

We Can Cover You

Healthcare

Lupin launches Doxorubicin Hydrochloride Liposome Injection in US, ET HealthWorld

Email :75

Mumbai: Lupin Limited announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials in the US after Lupin’s alliance partner, ForDoz Pharma Corporation, US, received approval for its ANDA from the United States Food and Drug Administration (US FDA).

Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials is a generic equivalent of Doxil (Liposomal), of Baxter Healthcare Corporation, indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil (Liposomal)) had an estimated annual sales of $40.9 million in the US (IQVIA MAT June 2024).

  • Published On Aug 29, 2024 at 10:12 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post